.2 (+ESI)
Rt: 1.39 min
Concentration: 2.16 ng/mL
m/z: 414.6-83.2
Rt: 1.20 min
Concentration: 642 ng/mL
Quantification of Buprenorphine and Norbuprenorphine with UHPLC-MS/MS
Buprenorphine is a synthetic
M NP_002261.3 y y y
203 Cytokeratin peptide 4 C5176 3851 KRT4 M NP_002263.2 y n/d n/d
205 Cytokeratin peptide 7 C6417 3855 KRT7 M NP_005547.3 y n/d n/d
206 Cytokeratin 8.12 C7034 3860 KRT13 M NP_002265.2
M NP_002261.3 y y y
203 Cytokeratin peptide 4 C5176 3851 KRT4 M NP_002263.2 y n/d n/d
205 Cytokeratin peptide 7 C6417 3855 KRT7 M NP_005547.3 y n/d n/d
206 Cytokeratin 8.12 C7034 3860 KRT13 M NP_002265.2
M NP_002261.3 y y y
203 Cytokeratin peptide 4 C5176 3851 KRT4 M NP_002263.2 y n/d n/d
205 Cytokeratin peptide 7 C6417 3855 KRT7 M NP_005547.3 y n/d n/d
206 Cytokeratin 8.12 C7034 3860 KRT13 M NP_002265.2
non-small cell lung cancer. PLos
One 7(12):e52984. PMID:23300840
9. Carthew, RW et al. (2009) Origins and Mechanisms of
miRNAs and siRNAs. Cell 136(4):642-55. PMID: 19239886
10. Carvalho, AT
Pur Rb IgG 200 µg 06-333
Anti-phospho-MAP Kinase1/2 (Erk1/2) H M R IP WB APur Sh IgG 100 µg 06-642
(Tyr180), polyclonal
Anti-phospho-MAP Kinase1/2 (Erk1/2) H R WR WB Pur Rb IgG 200 µg 07-467
Pur Rb IgG 200 µg 06-333
Anti-phospho-MAP Kinase1/2 (Erk1/2) H M R IP WB APur Sh IgG 100 µg 06-642
(Tyr180), polyclonal
Anti-phospho-MAP Kinase1/2 (Erk1/2) H R WR WB Pur Rb IgG 200 µg 07-467
d n/d
203 Cytokeratin peptide 4 C5176 M y n/d n/d
204 Cytokeratin CK5 C7785 M y n/d n/d
205 Cytokeratin peptide 7 C6417 M y n/d n/d
206 Cytokeratin 8.12 C7034 M y n/d n/d
207 Cytokeratin 8.13 C6909 M y
MIXTURE OF ISOMERS, 95% W247804 A58430 HC-23SIWU27
641. FENCHYL ALCOHOL W248010 C39743 HC-23SIMM53
642. FENNEL OIL, SWEET W248207 C49386 HC-23SI3G11
This is to certify that the following product(s) have
MIXTURE OF ISOMERS, 95% W247804 A58430 HC-22SIXW48
641. FENCHYL ALCOHOL W248010 C39743 HC-22SIHC74
642. FENNEL OIL, SWEET W248207 C49386 HC-22SI8Q32
This is to certify that the following product(s) have